Research | Brady Lab

Our long-term goal is to better understand and identify new treatment approaches for MASLD.

Metabolic dysfunction-associated steatotic liver disease (MASLD) - previously termed nonalcoholic fatty liver disease - is the most common chronic liver disease in the world, estimated to affect nearly one-third of the world’s adult population, with an incidence that is projected to continue growing over the next several decades.

The Brady Laboratory approaches MASLD from a unique angle, focusing on the nuclear envelope and lamina - which together make up a critical subcellular structure that is present in liver cells and all other nucleated cells and presents a promising new avenue for the development of treatments for MASLD. We use a combination of human genetics, cell culture studies, and in vivo models, and have been funded by the National Institutes of Health, American Liver Foundation, the Anna S.F. Lok, MD, Hepatology Breakthrough Fund, and the University of Michigan Medical School.

Find out more from our Publications list on PubMed